The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand
Open accessAbstract
BACKGROUND: The development of a safe and effective vaccine against the human immunodeficiency virus type 1 (HIV-1) is critical to pandemic control. METHODS: In a community-based, randomized, multicenter, double-blind, placebo-controlled efficacy trial, we evaluated four priming injections of a recombinant canarypox vector vaccine (ALVAC-HIV [vCP1521]) plus two booster injections of a recombinant glycoprotein 120 subunit vaccine (AIDSVAX B/E). The vaccine and placebo injections were administered to 16,402 healthy men and women between the ages of 18 and 30 years in Rayong and Chon Buri provinces in Thailand. The volunteers, primarily at heterosexual risk for HIV infection, were monitored for the coprimary end points: HIV-1 infection and early HIV-1 viremia, at the end of the 6-month vaccination series and every 6 months thereafter for 3 years. RESULTS: In the intention-to-treat analysis involving 16,402 subjects, there was a trend toward the prevention of HIV-1 infection among the vaccine recipients, with a vaccine efficacy of 26.4% (95% confidence interval [CI], -4.0 to 47.9; P=0.08). In the per-protocol analysis involving 12,542 subjects, the vaccine efficacy was 26.2% (95% CI, -13.3 to 51.9; P=0.16). In the modified intention-to-treat analysis involving 16,395 subjects (with the exclusion of 7 subjects who were found to have had HIV-1 infection at baseline), the vaccine efficacy was 31.2% (95% CI, 1.1 to 52.1; P=0.04). Vaccination did not affect the degree of viremia or the CD4+ T-cell count in subjects in whom HIV-1 infection was subsequently diagnosed. CONCLUSIONS: This ALVAC-HIV and AIDSVAX B/E vaccine regimen may reduce the risk of HIV infection in a community-based population with largely heterosexual risk. Vaccination did not affect the viral load or CD4+ count in subjects with HIV infection. Although the results show only a modest benefit, they offer insight for future research. (ClinicalTrials.gov number, NCT00223080.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Buchbinder, S. P., Mehrotra, D. V., Duerr, A., Fitzgerald, D. W., Mogg, R., Li, D., Gilbert, P. B., Lama, J. R., Marmor, M., del Rio, C., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61591-3 · Cited by 1,713
T-cell quality in memory and protection: implications for vaccine design
Seder, R. A., Darrah, P. A., & Roederer, M. (2008) · Nature Reviews Immunology · doi:10.1038/nri2274 · Cited by 1,548
The rgp120 HIV Vaccine Study Group (2005) · The Journal of Infectious Diseases · doi:10.1086/428404 · Cited by 952
Pitisuttithum, P., Gilbert, P., Gurwith, M., Heyward, W., Martin, M., van Griensven, F., Hu, D., Tappero, J. W., Choopanya, K., & Bangkok Vaccine Evaluation Group (2006) · The Journal of Infectious Diseases · doi:10.1086/508748 · Cited by 847
Self-citationSalazar-Gonzalez, J. F., Salazar, M. G., Keele, B. F., Learn, G. H., Giorgi, E. E., Li, H., Decker, J. M., Wang, S., Baalwa, J., Kraus, M. H., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090378 · Cited by 764
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis
McElrath, M. J., De Rosa, S. C., Moodie, Z., Dubey, S., Kierstead, L., Janes, H., Defawe, O. D., Carter, D. K., Hural, J., Akondy, R., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61592-5 · Cited by 713
Goonetilleke, N., Liu, M. K. P., Salazar-Gonzalez, J. F., Ferrari, G., Giorgi, E., Ganusov, V. V., Keele, B. F., Learn, G. H., Turnbull, E. L., Salazar, M. G., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090365 · Cited by 641
Mascola, J. R., Snyder, S. W., Weislow, O. S., Belay, S. M., Belshe, R. B., Schwartz, D. H., Clements, M. L., Dolin, R., Graham, B. S., Gorse, G. J., et al. (1996) · Journal of Infectious Diseases · doi:10.1093/infdis/173.2.340 · Cited by 436
Self-citationHanenberg, R. S., Sokal, D. C., Rojanapithayakorn, W., & Kunasol, P. (1994) · The Lancet · doi:10.1016/s0140-6736(94)93004-x · Cited by 435
Self-citationThe epidemiology of HIV infection and AIDS in Thailand
Weniger, B. G., Limpakarnjanarat, K., Ungchusak, K., Thanprasertsuk, S., Choopanya, K., Vanichseni, S., Uneklabh, T., Thongcharoen, P., & Wasi, C. (1991) · AIDS · doi:10.1097/00002030-199101001-00011 · Cited by 415
Self-citation
Cited by
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., Goicochea, P., Casapía, M., Guanira-Carranza, J. V., Ramirez-Cardich, M. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1011205 · Cited by 5,096
Abdool Karim, Q., Abdool Karim, S. S., Frohlich, J. A., Grobler, A. C., Baxter, C., Mansoor, L. E., Kharsany, A. B. M., Sibeko, S., Mlisana, K. P., Omar, Z., et al. (2010) · Science · doi:10.1126/science.1193748 · Cited by 2,435
Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial
Haynes, B. F., Gilbert, P. B., McElrath, M. J., Zolla-Pazner, S., Tomaras, G. D., Alam, S. M., Evans, D. T., Montefiori, D. C., Karnasuta, C., Sutthent, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113425 · Cited by 1,808
Self-citationA guide to vaccinology: from basic principles to new developments
Pollard, A. J., & Bijker, E. M. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00479-7 · Cited by 1,593
Immunological mechanisms of vaccination
Pulendran, B., & Ahmed, R. (2011) · Nature Immunology · doi:10.1038/ni.2039 · Cited by 1,089
Tameris, M. D., Hatherill, M., Landry, B. S., Scriba, T. J., Snowden, M. A., Lockhart, S., Shea, J. E., McClain, J. B., Hussey, G. D., Hanekom, W. A., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60177-4 · Cited by 1,049
The contribution of vaccination to global health: past, present and future
Greenwood, B. (2014) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2013.0433 · Cited by 979
The immune response during acute HIV-1 infection: clues for vaccine development
McMichael, A. J., Borrow, P., Tomaras, G. D., Goonetilleke, N., & Haynes, B. F. (2010) · Nature Reviews Immunology · doi:10.1038/nri2674 · Cited by 871
HIV infection: epidemiology, pathogenesis, treatment, and prevention
Maartens, G., Celum, C., & Lewin, S. R. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60164-1 · Cited by 830
Beyond binding: antibody effector functions in infectious diseases
Lu, L. L., Suscovich, T. J., Fortune, S. M., & Alter, G. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.106 · Cited by 825
Use of a vaginal ring containing dapivirine for HIV-1 prevention in women.
Baeten, J. M., Palanee-Phillips, T., Brown, E. R., Schwartz, K., Soto-Torres, L. E., Govender, V., Mgodi, N. M., Matovu Kiweewa, F., Nair, G., Mhlanga, F., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506110 · Cited by 772
Global trends in molecular epidemiology of HIV-1 during 2000–2007
Hemelaar, J., Gouws, E., Ghys, P. D., & Osmanov, S. (2011) · AIDS · doi:10.1097/qad.0b013e328342ff93 · Cited by 692
Deeks, S. G., Overbaugh, J., Phillips, A., & Buchbinder, S. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.35 · Cited by 644
Plotkin, S. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1400472111 · Cited by 642
Phillips, K. A., Bales, K. L., Capitanio, J. P., Conley, A., Czoty, P. W., ‘t Hart, B. A., Hopkins, W. D., Hu, S., Miller, L. A., Nader, M. A., et al. (2014) · American Journal of Primatology · doi:10.1002/ajp.22281 · Cited by 612
Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine
Hammer, S. M., Sobieszczyk, M. E., Janes, H., Karuna, S. T., Mulligan, M. J., Grove, D., Koblin, B. A., Buchbinder, S. P., Keefer, M. C., Tomaras, G. D., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310566 · Cited by 598
Self-citationProof of principle for epitope-focused vaccine design
Correia, B. E., Bates, J. T., Loomis, R. J., Baneyx, G., Carrico, C., Jardine, J. G., Rupert, P., Correnti, C., Kalyuzhniy, O., Vittal, V., et al. (2014) · Nature · doi:10.1038/nature12966 · Cited by 555
Targeting early infection to prevent HIV-1 mucosal transmission
Haase, A. T. (2010) · Nature · doi:10.1038/nature08757 · Cited by 593
HIV‐1 neutralizing antibodies: understanding nature's pathways
Mascola, J. R., & Haynes, B. F. (2013) · Immunological Reviews · doi:10.1111/imr.12075 · Cited by 475
Broadly Neutralizing Antiviral Antibodies
Corti, D., & Lanzavecchia, A. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095916 · Cited by 475
Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys
Barouch, D. H., Liu, J., Li, H., Maxfield, L. F., Abbink, P., Lynch, D. M., Iampietro, M. J., SanMiguel, A., Seaman, M. S., Ferrari, G., et al. (2012) · Nature · doi:10.1038/nature10766 · Cited by 465
Self-citationModern Subunit Vaccines: Development, Components, and Research Opportunities
Moyle, P. M., & Toth, I. (2013) · ChemMedChem · doi:10.1002/cmdc.201200487 · Cited by 464
Antibodies in HIV-1 Vaccine Development and Therapy
Klein, F., Mouquet, H., Dosenovic, P., Scheid, J. F., Scharf, L., & Nussenzweig, M. C. (2013) · Science · doi:10.1126/science.1241144 · Cited by 457
Yates, N. L., Liao, H.-X., Fong, Y., deCamp, A., Vandergrift, N. A., Williams, W. T., Alam, S. M., Ferrari, G., Yang, Z.-Y., Seaton, K. E., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007730 · Cited by 450
Self-citationDevelopments in Viral Vector-Based Vaccines
Ura, T., Okuda, K., & Shimada, M. (2014) · Vaccines · doi:10.3390/vaccines2030624 · Cited by 436
Cirelli, K. M., Carnathan, D. G., Nogal, B., Martin, J. T., Rodriguez, O. L., Upadhyay, A. A., Enemuo, C. A., Gebru, E. H., Choe, Y., Viviano, F., et al. (2019) · Cell · doi:10.1016/j.cell.2019.04.012 · Cited by 433
The origin and diversity of the HIV-1 pandemic
Hemelaar, J. (2012) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.12.001 · Cited by 427
Tam, H. H., Melo, M. B., Kang, M., Pelet, J. M., Ruda, V. M., Foley, M. H., Hu, J. K., Kumari, S., Crampton, J., Baldeon, A. D., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1606050113 · Cited by 425
Bonsignori, M., Hwang, K.-K., Chen, X., Tsao, C.-Y., Morris, L., Gray, E., Marshall, D. J., Crump, J. A., Kapiga, S. H., Sam, N. E., et al. (2011) · Journal of Virology · doi:10.1128/jvi.05045-11 · Cited by 423
Delany, I., Rappuoli, R., & De Gregorio, E. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201403876 · Cited by 420
Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2
Rolland, M., Edlefsen, P. T., Larsen, B. B., Tovanabutra, S., Sanders-Buell, E., Hertz, T., deCamp, A. C., Carrico, C., Menis, S., Magaret, C. A., et al. (2012) · Nature · doi:10.1038/nature11519 · Cited by 417
Self-citationChung, A. W., Ghebremichael, M., Robinson, H., Brown, E., Choi, I., Lane, S., Dugast, A.-S., Schoen, M. K., Rolland, M., Suscovich, T. J., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007736 · Cited by 406
Self-citationHemelaar, J., Elangovan, R., Yun, J., Dickson-Tetteh, L., Fleminger, I., Kirtley, S., Williams, B., Gouws-Williams, E., Ghys, P. D., Abimiku, A. G., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30647-9 · Cited by 405
Self-citationTomaras, G. D., Ferrari, G., Shen, X., Alam, S. M., Liao, H.-X., Pollara, J., Bonsignori, M., Moody, M. A., Fong, Y., Chen, X., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1301456110 · Cited by 394
Self-citationThe Role of Antibodies in HIV Vaccines
Mascola, J. R., & Montefiori, D. C. (2010) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101256 · Cited by 388
Antibody responses to envelope glycoproteins in HIV-1 infection
Burton, D. R., & Mascola, J. R. (2015) · Nature Immunology · doi:10.1038/ni.3158 · Cited by 385
Successes and challenges of HIV prevention in men who have sex with men
Sullivan, P. S., Carballo-Diéguez, A., Coates, T., Goodreau, S. M., McGowan, I., Sanders, E. J., Smith, A., Goswami, P., & Sanchez, J. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60955-6 · Cited by 382
Clinical Applications of DNA Vaccines: Current Progress
Ferraro, B., Morrow, M. P., Hutnick, N. A., Shin, T. H., Lucke, C. E., & Weiner, D. B. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir334 · Cited by 381
Design of virus-based nanomaterials for medicine, biotechnology, and energy
Wen, A. M., & Steinmetz, N. F. (2016) · Chemical Society Reviews · doi:10.1039/c5cs00287g · Cited by 379
Liao, H.-X., Bonsignori, M., Alam, S. M., McLellan, J. S., Tomaras, G. D., Moody, M. A., Kozink, D. M., Hwang, K.-K., Chen, X., Tsao, C.-Y., et al. (2013) · Immunity · doi:10.1016/j.immuni.2012.11.011 · Cited by 377
Self-citationBonsignori, M., Pollara, J., Moody, M. A., Alpert, M. D., Chen, X., Hwang, K.-K., Gilbert, P. B., Huang, Y., Gurley, T. C., Kozink, D. M., et al. (2012) · Journal of Virology · doi:10.1128/jvi.01023-12 · Cited by 375
Self-citationUse of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women
Baeten, J. M., Palanee-Phillips, T., Brown, E. R., Schwartz, K., Soto-Torres, L. E., Govender, V., Mgodi, N. M., Kiweewa, F. M., Nair, G., Mhlanga, F., et al. (2016) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000489577.60775.40 · Cited by 372
Recombinant vaccines and the development of new vaccine strategies
Nascimento, I. P., & Leite, L. C. C. (2012) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2012007500142 · Cited by 367
Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity
Ackerman, M. E., Crispin, M., Yu, X., Baruah, K., Boesch, A. W., Harvey, D. J., Dugast, A.-S., Heizen, E. L., Ercan, A., Choi, I., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65708 · Cited by 358
Viruses as vaccine vectors for infectious diseases and cancer
Draper, S. J., & Heeney, J. L. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2240 · Cited by 353
Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology
Chung, A. W., Kumar, M. P., Arnold, K. B., Yu, W. H., Schoen, M. K., Dunphy, L. J., Suscovich, T. J., Frahm, N., Linde, C., Mahan, A. E., et al. (2015) · Cell · doi:10.1016/j.cell.2015.10.027 · Cited by 352
Self-citationStrategies for HIV-1 vaccines that induce broadly neutralizing antibodies
Haynes, B. F., Wiehe, K., Borrow, P., Saunders, K. O., Korber, B., Wagh, K., McMichael, A. J., Kelsoe, G., Hahn, B. H., Alt, F., et al. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00753-w · Cited by 352
Barouch, D. H., Stephenson, K. E., Borducchi, E. N., Smith, K., Stanley, K., McNally, A. G., Liu, J., Abbink, P., Maxfield, L. F., Seaman, M. S., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.061 · Cited by 342
Self-citationTargeting the Latent Reservoir for HIV-1
Sengupta, S., & Siliciano, R. F. (2018) · Immunity · doi:10.1016/j.immuni.2018.04.030 · Cited by 340
Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination
Schmidt, T., Klemis, V., Schub, D., Mihm, J., Hielscher, F., Marx, S., Abu-Omar, A., Ziegler, L., Guckelmus, C., Urschel, R., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01464-w · Cited by 340
Barouch, D. H., Tomaka, F. L., Wegmann, F., Stieh, D. J., Alter, G., Robb, M. L., Michael, N. L., Peter, L., Nkolola, J. P., Borducchi, E. N., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31364-3 · Cited by 336
Self-citationPast, present and future: 30 years of HIV research
Barré-Sinoussi, F., Ross, A. L., & Delfraissy, J.-F. (2013) · Nature Reviews Microbiology · doi:10.1038/nrmicro3132 · Cited by 332
Combination HIV Prevention: Significance, Challenges, and Opportunities
Kurth, A. E., Celum, C., Baeten, J. M., Vermund, S. H., & Wasserheit, J. N. (2011) · Current HIV/AIDS Reports · doi:10.1007/s11904-010-0063-3 · Cited by 329
Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning
Kwong, P. D., Mascola, J. R., & Nabel, G. J. (2013) · Nature Reviews Immunology · doi:10.1038/nri3516 · Cited by 329
Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens
Doores, K. J., Bonomelli, C., Harvey, D. J., Vasiljevic, S., Dwek, R. A., Burton, D. R., Crispin, M., & Scanlan, C. N. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006498107 · Cited by 329
Early Events in Sexual Transmission of HIV and SIV and Opportunities for Interventions
Haase, A. T. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-080709-124959 · Cited by 321
The use of viral vectors in vaccine development
Travieso, T., Li, J., Mahesh, S., Mello, J. D. F. R. E., & Blasi, M. (2022) · npj Vaccines · doi:10.1038/s41541-022-00503-y · Cited by 310
CD8+ T cells in HIV control, cure and prevention
Collins, D. R., Gaiha, G. D., & Walker, B. D. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0274-9 · Cited by 303
Klein, S. L. (2012) · BioEssays · doi:10.1002/bies.201200099 · Cited by 284
Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys
Barouch, D. H., Alter, G., Broge, T., Linde, C., Ackerman, M. E., Brown, E. P., Borducchi, E. N., Smith, K. M., Nkolola, J. P., Liu, J., et al. (2015) · Science · doi:10.1126/science.aab3886 · Cited by 297
High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men
Li, H., Bar, K. J., Wang, S., Decker, J. M., Chen, Y., Sun, C., Salazar-Gonzalez, J. F., Salazar, M. G., Learn, G. H., Morgan, C. J., et al. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000890 · Cited by 297
HIV prevention transformed: the new prevention research agenda
Padian, N. S., McCoy, S. I., Karim, S. S. A., Hasen, N., Kim, J., Bartos, M., Katabira, E., Bertozzi, S. M., Schwartländer, B., & Cohen, M. S. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60877-5 · Cited by 295
Self-citationDefeating AIDS—advancing global health
Piot, P., Abdool Karim, S. S., Hecht, R., Legido-Quigley, H., Buse, K., Stover, J., Resch, S., Ryckman, T., Møgedal, S., Dybul, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60658-4 · Cited by 293
Understanding and learning from the success of prophylactic human papillomavirus vaccines
Schiller, J. T., & Lowy, D. R. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2872 · Cited by 293
Bomsel, M., Tudor, D., Drillet, A.-S., Alfsen, A., Ganor, Y., Roger, M.-G., Mouz, N., Amacker, M., Chalifour, A., Diomede, L., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.01.015 · Cited by 293
Montefiori, D. C., Karnasuta, C., Huang, Y., Ahmed, H., Gilbert, P., de Souza, M. S., McLinden, R., Tovanabutra, S., Laurence-Chenine, A., Sanders-Buell, E., et al. (2012) · Journal of Infectious Diseases · doi:10.1093/infdis/jis367 · Cited by 284
Self-citationTherapeutic Cancer Vaccines: Current Status and Moving Forward
Schlom, J. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs033 · Cited by 282
HIV-Specific Cytolytic CD4 T Cell Responses During Acute HIV Infection Predict Disease Outcome
Soghoian, D. Z., Jessen, H., Flanders, M., Sierra-Davidson, K., Cutler, S., Pertel, T., Ranasinghe, S., Lindqvist, M., Davis, I., Lane, K., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003165 · Cited by 279
COMPASS identifies T-cell subsets correlated with clinical outcomes
Lin, L., Finak, G., Ushey, K., Seshadri, C., Hawn, T. R., Frahm, N., Scriba, T. J., Mahomed, H., Hanekom, W., Bart, P.-A., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3187 · Cited by 278
Self-citationCurrent status and challenges of antiretroviral research and therapy
Esté, J. A., & Cihlar, T. (2010) · Antiviral Research · doi:10.1016/j.antiviral.2009.10.007 · Cited by 277
A 2020 vision for vaccines against HIV, tuberculosis and malaria
Rappuoli, R., & Aderem, A. (2011) · Nature · doi:10.1038/nature10124 · Cited by 273
Nabel, G. J. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1204186 · Cited by 271
Few and Far Between: How HIV May Be Evading Antibody Avidity
Klein, J. S., & Bjorkman, P. J. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000908 · Cited by 271
Induction of Immunity to Human Immunodeficiency Virus Type-1 by Vaccination
McElrath, M. J., & Haynes, B. F. (2010) · Immunity · doi:10.1016/j.immuni.2010.09.011 · Cited by 270
Zolla-Pazner, S., deCamp, A., Gilbert, P. B., Williams, C., Yates, N. L., Williams, W. T., Howington, R., Fong, Y., Morris, D. E., Soderberg, K. A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087572 · Cited by 267
Self-citationIrrgang, P., Gerling, J., Kocher, K., Lapuente, D., Steininger, P., Habenicht, K., Wytopil, M., Beileke, S., Schäfer, S., Zhong, J., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.ade2798 · Cited by 264
Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice
Dosenovic, P., von Boehmer, L., Escolano, A., Jardine, J., Freund, N. T., Gitlin, A. D., McGuire, A. T., Kulp, D. W., Oliveira, T., Scharf, L., et al. (2015) · Cell · doi:10.1016/j.cell.2015.06.003 · Cited by 263
Burton, D. R., Hessell, A. J., Keele, B. F., Klasse, P. J., Ketas, T. A., Moldt, B., Dunlop, D. C., Poignard, P., Doyle, L. A., Cavacini, L., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1103012108 · Cited by 255
Nonhuman primate models of human viral infections
Estes, J. D., Wong, S. W., & Brenchley, J. M. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0005-7 · Cited by 255
Duerr, A., Huang, Y., Buchbinder, S., Coombs, R. W., Sanchez, J., del Rio, C., Casapia, M., Santiago, S., Gilbert, P., Corey, L., et al. (2012) · Journal of Infectious Diseases · doi:10.1093/infdis/jis342 · Cited by 210
Viral vectors as vaccine platforms: deployment in sight
Rollier, C. S., Reyes-Sandoval, A., Cottingham, M. G., Ewer, K., & Hill, A. V. (2011) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.03.006 · Cited by 203
Nonneutralizing Functional Antibodies: a New “Old” Paradigm for HIV Vaccines
Excler, J.-L., Ake, J., Robb, M. L., Kim, J. H., & Plotkin, S. A. (2014) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00230-14 · Cited by 114
Self-citationViral vectors for vaccine applications
Choi, Y., & Chang, J. (2013) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2013.2.2.97 · Cited by 112
Peptides for Vaccine Development
Hamley, I. W. (2022) · ACS Applied Bio Materials · doi:10.1021/acsabm.1c01238 · Cited by 104
Casazza, J. P., Cale, E. M., Narpala, S., Yamshchikov, G. V., Coates, E. E., Hendel, C. S., Novik, L., Holman, L. A., Widge, A. T., Apte, P., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01762-x · Cited by 91
Giannou, F. K., Tsiara, C. G., Nikolopoulos, G. K., Talias, M., Benetou, V., Kantzanou, M., Bonovas, S., & Hatzakis, A. (2016) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.2016.1102635 · Cited by 85
Proteome-wide analysis of HIV-specific naive and memory CD4+ T cells in unexposed blood donors
Campion, S. L., Brodie, T. M., Fischer, W., Korber, B. T., Rossetti, A., Goonetilleke, N., McMichael, A. J., & Sallusto, F. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20130555 · Cited by 84
Barnett, S. W., Burke, B., Sun, Y., Kan, E., Legg, H., Lian, Y., Bost, K., Zhou, F., Goodsell, A., zur Megede, J., et al. (2010) · Journal of Virology · doi:10.1128/jvi.02533-09 · Cited by 82
“Importantly, the same general vaccine concept of vector prime plus Env protein boost yielded the first ever positive HIV vaccine efficacy results in Thailand whereby a prime-boost regimen of Sanofi-Pasteur’s recombinant HIV canary pox (ALVAC-HIV) vaccine combined with VaxGen’s bivalent monomeric gp120 (AIDSVAX B/E) va…”
BackgroundResultGolding, H., Khurana, S., & Zaitseva, M. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028902 · Cited by 67
A general inefficacy interim monitoring rule for randomized clinical trials
Freidlin, B., Korn, E. L., & Gray, R. (2010) · Clinical Trials · doi:10.1177/1740774510369019 · Cited by 64
Shangguan, S., Ehrenberg, P. K., Geretz, A., Yum, L., Kundu, G., May, K., Fourati, S., Nganou-Makamdop, K., Williams, L. D., Sawant, S., et al. (2021) · eLife · doi:10.7554/elife.69577 · Cited by 26
Self-citationDennison, S. M., Anasti, K. M., Jaeger, F. H., Stewart, S. M., Pollara, J., Liu, P., Kunz, E. L., Zhang, R., Vandergrift, N., Permar, S., et al. (2014) · Journal of Virology · doi:10.1128/jvi.01031-14 · Cited by 18
Self-citation
Metadata
- Authors
- Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Chiu, J., Paris, R., Premsri, N., Namwat, C., de Souza, M., Adams, E., Benenson, M., Gurunathan, S., Tartaglia, J., McNeil, J. G., Francis, D. P., Stablein, D., Birx, D. L., Chunsuttiwat, S., Khamboonruang, C., Thongcharoen, P., Robb, M. L., Michael, N. L., Kunasol, P., & Kim, J. H.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-12-03
- Volume
- 361
- Issue
- 23
- Pages
- 2209-2220
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2152048324
- Cited by
- 3,034
- References
- 28
- FWCI
- 97.23
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.